Pharmacokinetic evaluation of transdermal buprenorphine in man

International Journal of Pharmaceutics

Volumn 132, Issue 1-2, 1996, Pages 81-87

  Wilding, I R ^a   Davis, S S ^a   Rimoy, G H ^b   Rubin, P ^b   Kurihara Bergstrom, T ^c   Tipnis, V ^c   Berner, B ^c   Nightingale, J ^c,d  

^a PHARMACEUTICAL PROFILES LTD   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Bend Research Incorporated   (United States)

Author keywords

Buprenorphine; Man; Pharmacokinetic evaluation; Transdermal

Indexed keywords

ALCOHOL; BUPRENORPHINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG SAFETY; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN ABSORPTION; SKIN IRRITATION; TRANSDERMAL DRUG ADMINISTRATION; VOLUNTEER;

EID: 0029895196     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-5173(96)85198-2     Document Type: Article

References (16)

1. Adrianensen, H., Mattlaer, B. and Vanmeenen, H., A long-term open, clinical and pharmacokinetic assessment of sublingual buprenorphine in patients suffering from chronic pain. Acta Anaesthesiol. Biol., 1 (1985) 33-40.
2. Amass, L., Bickel, W.K., Higgins, S.T. and Badger, G.J., Alternate-day dosing during buprenorphine treatment of opoid dependence. Life Sci., 54 (1994) 1215-1228.
3. Bullingham, R.E.S., McQuay, H.J., Moore, A. and Bennett, M.D.R., Buprenorphine kinetics. Clin. Pharm. Ther., 28 (1980) 667-672.
4. Downing, J.W., Leary, W.P. and White, E.S., Buprenorphine: a new potent long-acting synthetic analgesic. Comparison with morphine. Br. J. Anaesth., 49 (1977) 251-255.
5. Granger, C.D., A transdermal delivery system containing buprenorphine for treatment of cocaine and heroin addiction. Eur. Pat. Appl. EP 432945 (19 June 1991).
6. Hambrook, J.M. and Rance, M.J., The interaction of buprenorphine with opiate receptor. In Kosterlitz, H.W. (Ed.), Opiates and Endogenous Opioid Peptides, Elsevier/ North Holland Biomedical Press, Amsterdam, 1976, pp. 295-301.
7. Hidaka, O. and Murakami, S., Flexible and durable pharmaceutical transdermal tapes. PCT Int. Appl. WO 9116 044 (31 October 1991).
8. Hille, T., Deuer, L. and Hoffmann, H.R., Transdermal therapeutic system for buprenorphine delivery. Ger. Pat. DE 3939376 (8 May 1991).
9. Jasinski, D.R., Pevnick, J.S, and Griffith, J.D., Human pharmacology and abuse potential of the analgesic buprenorphine. Arch. Gen. Psychiatry, 35 (1978) 501-516.
10. Lewis, J.W., Buprenorphine. Drug and Alcohol Dependence, 14 (1985) 363-372.
11. Nightingale, J., Kurihara-Bergstrom, T., Kochak, G., Rubin, P., Wilding, I.R. and Davis, S.S., Transition from in vitro to clinical trials: Application of fillable TTS in transdermal formulation development. Pharm. Res., 9 (1992a) S190.
12. Nightingale, J., Kurihara-Bergstrom, T., Mirley, C., Signor, C. and DeNoble, L., In vitro transdermal delivery of buprenorphine hydrochloride. In Kopecek, J. (Ed.), Proc. 19th Int. Symp. Controlled Release Bioact. Mater., Controlled Release Soc., Deerfield, 1992b, pp. 246-247.
13. Roy, S.D., Roos, E. and Sharma, K., Transdermal delivery of buprenorphine through cadaver skin. J. Pharm. Sci., 83 (1994) 126-130.
14. Strain, E.C., Stitzer, M.L., Liebson, L.A. and Bigelow, G.E., Comparison of buprenorphine and methadone in the treatment of opiod dependence. Am. J. Psychiatry, 151 (1994) 25-1030.
15. Szuktak, J.B., Manring, G.L., Smith, R.L. and Drust, E.G., Topical pharmaceuticals containing buprenorphine salts. Eur. Pat. Appl. EP 368409 (16 May 1990).
16. Walsh, S.L., Preston, K.L., Stitzer, M.L., Cone, E.J. and Bigelow, G.E., Clinical Pharmacology of buprenorphine: Ceiling effects at high doses, Clin. Pharamacol. Ther., 55 (1994) 569-80.